Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-PGPIKVAV
- Development stage
- Preclinical
- Lead developer
- Babasaheb Bhimrao Ambedkar University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Topical
01
Overview
99mTc-PGPIKVAV is a technetium-99m radiolabeled laminin-derived peptide (PGPIKVAV) formulated in a sodium carboxymethylcellulose (CMC) hydrogel. It is developed as a single-photon emission computed tomography (SPECT) imaging probe for the non-invasive assessment of wound healing severity and progress. The PGPIKVAV peptide mimics laminin, a structural component of the basement membrane, and interacts with integrin receptors (such as α3β1, αvβ3, and α5β1) and CXCR2 on cell surfaces to promote cell migration, proliferation, differentiation, and angiogenesis. The radiolabeled hydrogel remains localized at the topical wound site for 12 to 24 hours, allowing for SPECT imaging of the wound healing process.
- Other names
- 99mTc-PGPIKVAV hydrogeltechnetium Tc 99m PGPIKVAVtechnetium-99m PGPIKVAVtechnetium99m PGPIKVAVtechnetium 99m PGPIKVAV
02
Targets
CXCR2 (C-X-C Motif Chemokine Receptor 2)α3β1 (Integrin alpha 3 beta 1)ITGA5:ITGB1 (Integrin α5β1)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on 99mTc-PGPIKVAV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-PGPIKVAV.